Immunovant Inc.
IMVT | NASDAQ
$37.18
+$0.23 (+0.62%)
At close: Sep 21, 2026, 4:00 PM ET
$37.16
-$0.02 (-0.05%)
Pre-market:
Sep 22, 2026, 8:31 AM ET
Fiscal Year Period Ending | FY 2026 Mar 30, 2026 | FY 2025 Mar 30, 2025 | FY 2024 Mar 30, 2024 | FY 2023 Mar 30, 2023 | FY 2022 Mar 30, 2022 | FY 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 409K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -409K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -532.9M | -438.15M | -270.21M | -208.28M | -156.03M | -108.12M |
Interest Income | 25.33M | 24.73M | 24.95M | 7.58M | n/a | n/a |
Pretax Income | -505.39M | -412.95M | -258.77M | -210.95M | -156.81M | -107.79M |
Net Income | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M | -107.43M |
Selling & General & Admin | 76.24M | 77.24M | 57.28M | 48.02M | 54.23M | 39.51M |
Research & Development | 456.66M | 360.92M | 212.93M | 160.26M | 101.81M | 68.6M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 532.9M | 438.15M | 270.21M | 208.28M | 156.03M | 108.12M |
Interest Expense | n/a | n/a | n/a | 12.48M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 532.9M | 438.15M | 270.21M | 208.28M | 156.03M | 108.12M |
Income Tax Expense | 215K | 891K | 567K | 9K | -84K | -358K |
Shares Outstanding (Basic) | 182.42M | 151.57M | 138.1M | 123.08M | 109.68M | 87.76M |
Shares Outstanding (Diluted) | 182.42M | 151.57M | 138.1M | 123.08M | 109.68M | 87.76M |
EPS (Basic) | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 |
EPS (Diluted) | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 |
EBITDA | -504.98M | -412.57M | -258.54M | -198.28M | -156.69M | -108.05M |
EBIT | -505.39M | -412.95M | -258.77M | -198.47M | -156.81M | -108.12M |
Depreciation & Amortization | 409K | 377K | 231K | 193K | 126K | 65K |
Add to Watchlist
Select watchlists to add or remove IMVT